Post Marketing Surveillance Study for ONIVYDE® in South Korea

• ONIVYDE (Drug): irinotecan liposome injection
• 5-fluorouracil (Drug), also known as 5-FU, fluorouracil: a nucleoside metabolic inhibitor
• Leucovorin (Drug), also known as LV: an active metabolite of folic acid

Primary outcomes

• Number of Adverse Events (AEs) [Throughout the study period approximately 4 years]: Number of AEs by seriousness and severity
• Grade 3 and 4 neutropenia cases [Throughout the study period approximately 4 years]: Frequency of Grade 3 and 4 neutropenia cases

Secondary outcomes

• Visit Information: Number of Visit Types [Throughout the study period approximately 4 years]: Number of: Outpatient/office Visits, In-hospital Visits, Phone Visits, or Other Types Visits
• Visit Information: Reason for Visits [Throughout the study period approximately 4 years]: Number of: Scheduled Visits, Emergency Visits, Other Types Visits
• Median Dose of ONIVYDE [Throughout the study period approximately 4 years]: Median Dose of ONIVYDE administered during the study period
• Median Dose of fluorouracil [Throughout the study period approximately 4 years]: Median Dose of fluorouracil administered during the study period
• Median Dose of Leucovorin [Throughout the study period approximately 4 years]: Median Dose of Leucovorin administered during the study period
• Overall response [Throughout the study period approximately 4 years]: Response duration usually is measured from the time of initial response until documented tumor progression.
• Overall Survival [Throughout the study period approximately 4 years]: The time from enrollment to death from any cause, is a direct measure of clinical benefit to a patient.
• Progression free survival [Throughout the study period approximately 4 years]: The time elapsed between treatment initiation and tumor progression or death from any cause.
• Quality of Life assessment (EQ-5D-5 L Health Questionnaire) [Baseline, and then every 3 weeks, and at the end of study visit up to approximately 4 years]: The instrument that measures conceptual domains of quality of patients' well-being.

Sex: All, ages: 19 Years to any

Inclusion Criteria:

Patients who are prescribed ONIVYDE per investigator's judgment shall be included if:

* Patient / legally authorized representative/ family member gave written informed consent
* Patient is indicated for treatment according to ONIVYDE South Korea prescribing information
* Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas
* Documented metastatic disease
* Patient deemed not eligible or failed previous treatment with gemcitabine or gemcitabine containing therapy
* Adequate hepatic, renal and hematological function

Exclusion Criteria:

* Patients enrolled in Servier sponsored ONIVYDE Registry or any other Servier sponsored ONIVYDE study
* Patients who have experienced severe hypersensitivity reaction to ONIVYDE or Irinotecan HCL
* Patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation of interstitial lung disease. Patients with confirmed diagnosis of interstitial lung disease